T1CARE: A program to address social needs for young adults with Type 1 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized controlled trial with a 1:1 allocation to the T1CARE intervention or a wait-list usual care arm, recruiting from Yale Adult and Pediatric Diabetes Centers. Participants assigned to T1CARE receive individualized support from a Community Health Navigator through Project Access-New Haven to address health-related social needs. The primary outcome is resolution of those social needs, with secondary measures of feasibility, acceptability, patient-reported outcomes (including diabetes distress, illness intrusiveness, and quality of life), and preliminary effects on HbA1c. The design includes a wait-list control so usual-care participants can later access the intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Type 1 Diabetes
* fluent in Spanish or English who reside in the greater New Haven area

Exclusion Criteria:

* cognitive impairment and otherwise unable to give written informed consent about participating in this study

Where it's running

• Yale Adult Diabetes Center
  New Haven, Connecticut, United States Recruiting
• Yale Children's Diabetes Center
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Kasia Lipska, MD, MHS — Yale University
• Study coordinator: Kasia J Lipska, MD
• Email: Kasia.lipska@yale.edu
• Phone: 203-500-3053

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity

  This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07891156

• Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes

  This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.

  Recruiting at 11 sites Medtronic MiniMed, Inc. · Chula Vista, California and 17 other locations · NCT07864168

• CGM-guided carb awareness education for adults with Type 1 diabetes

  This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.

  Recruiting University of California, Los Angeles · Los Angeles, California · NCT07807280

• Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes

  This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.

  Recruiting at 17 sites Indiana University · Newport Beach, California and 16 other locations · NCT07676565

• Think-Find-Solve activities for insulin self-management in children with type 1 diabetes

  A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.

  Recruiting Marmara University · Istanbul · NCT07670572

• Near-sensor insulin delivery with CGM in people with type 1 diabetes

  A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.

  Recruiting Early Phase 1 ClinSurge Research · Toronto, Ontario · NCT07655076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.